Skip Navigation


European Heart Journal Advance Access originally published online on November 29, 2006
European Heart Journal 2007 28(1):26-32; doi:10.1093/eurheartj/ehl412
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
28/1/26    most recent
ehl412v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (38)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Daemen, J.
Right arrow Articles by Serruys, P. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Daemen, J.
Right arrow Articles by Serruys, P. W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus

Joost Daemen, Hector M. Garcia-Garcia, Neville Kukreja, Farshad Imani, Peter P.T. de Jaegere, Georgios Sianos, Ron T. van Domburg and Patrick W. Serruys*

Thoraxcenter, Erasmus Medical Center, Ba-583 Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands

Received 23 August 2006; revised 8 October 2006; accepted 9 November 2006; online publish-ahead-of-print 29 November 2006.

* Corresponding author. Tel: +31 10 4635260; fax: +31 10 4369154. E-mail address: p.w.j.c.serruys{at}erasmusmc.nl

Aims To investigate the outcome of a real world diabetic patient cohort treated with bare metal stents (BMS), sirolimus-, or paclitaxel-eluting stents (SES and PES, respectively). Due to the different mechanisms of action of both drugs it is currently unknown which device is the best option to treat these high-risk patients.

Methods and results The study compares the 2-year clinical outcome of 708 consecutive diabetic patients (25% insulin treated) treated with either a BMS (n = 252), a SES (n = 206), or a PES (n = 250), as part of the RESEARCH and T-SEARCH registries. Target vessel revascularization was 19.5% in the BMS group, vs. 15.3% in the SES group and 9.7% in the PES group. PES (21.2%), but not SES (28.9%), were superior to BMS (29.7%) in reducing major adverse cardiac events. After propensity analyses, none of the differences remained significant. The incidence of stent thrombosis (ST) was high in both DES groups.

Conclusion There was a trend towards a more favourable outcome associated with the use of PES over BMS. There was no significant difference between SES and PES in each of the clinical endpoints, and neither in the NIDDM patients, which are hypothesized to be better-off with PES.

Key Words: Diabetes • Sirolimus-eluting stent • Paclitaxel-eluting stent • Restenosis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Am Coll Cardiol IntvHome page
A. J. Kirtane, R. Patel, C. O'Shaughnessy, P. Overlie, B. McLaurin, S. Solomon, L. Mauri, P. Fitzgerald, J. J. Popma, D. E. Kandzari, et al.
Clinical and Angiographic Outcomes in Diabetics From the ENDEAVOR IV Trial: Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease
J. Am. Coll. Cardiol. Intv., October 1, 2009; 2(10): 967 - 976.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
G. Weisz, M. B. Leon, D. R. Holmes Jr, D. J. Kereiakes, J. J. Popma, P. S. Teirstein, S. A. Cohen, H. Wang, D. E. Cutlip, and J. W. Moses
Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial.
J. Am. Coll. Cardiol., April 28, 2009; 53(17): 1488 - 1497.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S.-W. Lee, S.-W. Park, Y.-H. Kim, S.-C. Yun, D.-W. Park, C. W. Lee, M.-K. Hong, K.-S. Rhee, J. K. Chae, J.-K. Ko, et al.
A Randomized Comparison of Sirolimus- Versus Paclitaxel-Eluting Stent Implantation in Patients With Diabetes Mellitus 2-Year Clinical Outcomes of the DES-DIABETES Trial.
J. Am. Coll. Cardiol., March 3, 2009; 53(9): 812 - 813.
[Full Text] [PDF]

Home page
 J Am Coll Cardiol IntvHome page
E. Mahmud, J. A. Ormiston, M. A. Turco, J. J. Popma, N. J. Weissman, C. D. O'Shaughnessy, T. Mann, J. J. Hall, T. F. McGarry, L. A. Cannon, et al.
TAXUS Liberte Attenuates the Risk of Restenosis in Patients With Medically Treated Diabetes Mellitus: Results From the TAXUS ATLAS Program
J. Am. Coll. Cardiol. Intv., March 1, 2009; 2(3): 240 - 252.
[Abstract] [Full Text] [PDF]

Home page
 Circ Cardiovasc Qual OutcomesHome page
M. Chiu, D. T. Ko, P. C. Austin, E. A. Cohen, J. L. Velianou, R. Goeree, G. Blackhouse, and J. V. Tu
Paclitaxel Versus Sirolimus Stents in Diabetic and Nondiabetic Patients
Circ Cardiovasc Qual Outcomes, March 1, 2009; 2(2): 96 - 107.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. Daemen, K. H. Kuck, C. Macaya, V. LeGrand, M. Vrolix, D. Carrie, I. Sheiban, M. J. Suttorp, P. Vranckx, T. Rademaker, et al.
Multivessel Coronary Revascularization in Patients With and Without Diabetes Mellitus: 3-Year Follow-Up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) Trial
J. Am. Coll. Cardiol., December 9, 2008; 52(24): 1957 - 1967.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
P. Garg, S.-L. T. Normand, T. S. Silbaugh, R. E. Wolf, K. Zelevinsky, A. Lovett, M. R. Varma, Z. Zhou, and L. Mauri
Drug-Eluting or Bare-Metal Stenting in Patients With Diabetes Mellitus: Results From the Massachusetts Data Analysis Center Registry
Circulation, November 25, 2008; 118(22): 2277 - 2285.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S.-W. Lee, S.-W. Park, Y.-H. Kim, S.-C. Yun, D.-W. Park, C. W. Lee, M.-K. Hong, K.-S. Rhee, J. K. Chae, J.-K. Ko, et al.
A Randomized Comparison of Sirolimus- Versus Paclitaxel-Eluting Stent Implantation in Patients With Diabetes Mellitus
J. Am. Coll. Cardiol., August 26, 2008; 52(9): 727 - 733.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
E. Mahmud, G. Bromberg-Marin, V. Palakodeti, L. Ang, D. Creanga, and A. N. DeMaria
Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis.
J. Am. Coll. Cardiol., June 24, 2008; 51(25): 2385 - 2395.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
M. Billinger, J. Beutler, K. R. Taghetchian, A. Remondino, P. Wenaweser, S. Cook, M. Togni, C. Seiler, C. Stettler, F. R. Eberli, et al.
Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients
Eur. Heart J., March 2, 2008; 29(6): 718 - 725.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
A. J. Kirtane, S. G. Ellis, K. D. Dawkins, A. Colombo, E. Grube, J. J. Popma, M. Fahy, M. B. Leon, J. W. Moses, R. Mehran, et al.
Paclitaxel-Eluting Coronary Stents in Patients With Diabetes Mellitus Pooled Analysis From 5 Randomized Trials.
J. Am. Coll. Cardiol., February 19, 2008; 51(7): 708 - 715.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
P. Ortolani, M. Balducelli, P. Marzaroli, G. Piovaccari, A. Menozzi, V. Guiducci, P. Sangiorgio, F. Tarantino, G. Geraci, F. Castriota, et al.
Two-Year Clinical Outcomes With Drug-Eluting Stents for Diabetic Patients With De Novo Coronary Lesions: Results From a Real-World Multicenter Registry
Circulation, February 19, 2008; 117(7): 923 - 930.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
F. Tomai, B. Reimers, L. De Luca, A. R. Galassi, A. Gaspardone, A. S. Ghini, V. Ferrero, L. Favero, G. Gioffre, F. Prati, et al.
Head-to-Head Comparison of Sirolimus- and Paclitaxel-Eluting Stent in the Same Diabetic Patient With Multiple Coronary Artery Lesions: A prospective, randomized, multicenter study
Diabetes Care, January 1, 2008; 31(1): 15 - 19.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
A. E. Rodriguez, A. O. Maree, J. Mieres, D. Berrocal, L. Grinfeld, C. Fernandez-Pereira, V. Curotto, A. Rodriguez-Granillo, W. O'Neill, and I. F. Palacios
Late loss of early benefit from drug-eluting stents when compared with bare-metal stents and coronary artery bypass surgery: 3 years follow-up of the ERACI III registry
Eur. Heart J., September 1, 2007; 28(17): 2118 - 2125.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. Daemen and P. W. Serruys
Drug-Eluting Stent Update 2007: Part II: Unsettled Issues
Circulation, August 21, 2007; 116(8): 961 - 968.
[Full Text] [PDF]

Home page
 NEJMHome page
C. Spaulding, J. Daemen, E. Boersma, D. E. Cutlip, and P. W. Serruys
A Pooled Analysis of Data Comparing Sirolimus-Eluting Stents with Bare-Metal Stents
N. Engl. J. Med., March 8, 2007; 356(10): 989 - 997.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.